 |
인쇄하기
취소
|
Handok, Lilly Korea to join forces in Cymbalta
Lilly Korea and Handok Pharm said on June 22 that they have agreed to join hands to market Cymbalta (duloxetine HCl) in Korea.
To this end, the two companies exchanged a letter of intent to make Cymbalta more competitive in domestic market.
Cymbalta, part of a class of drugs called serotonin-norepinephrine reuptake inhibitors (SNRIs), is often prescribed to treat conditions such as depres...
To this end, the two companies exchanged a letter of intent to make Cymbalta more competitive in domestic market.
Cymbalta, part of a class of drugs called serotonin-norepinephrine reuptake inhibitors (SNRIs), is often prescribed to treat conditions such as depres...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.